Photo by Chris Montgomery on Unsplash
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
This year’s Life Sciences Investor Forum, running from 9:30 a.m. to 3:30 p.m. Dec. 16, introduces 12 publicly listed life science companies aiming to improve the quality of human life.
From biopharmaceuticals and epigenetics to psychedelics and metabolic health, each company has chosen a niche through which to achieve this goal. Attendees, investors and stakeholders will watch and listen as each of these companies explains their latest ideas, prompting watchers to wonder: What new scientific development will change human life as we know it?
For ReShape Lifesciences Inc. RSLS, the answer to this question may reportedly lie in its Food and Drug Administration (FDA)-approved Lap-Band® Program, which provides a minimally invasive, long-term treatment for obesity. Meanwhile, VolitionRx Ltd. VNRX will argue that its Nucleosomics™ platform will radically improve patients’ ability to catch and monitor life-changing diseases early. Mind Cure Health Inc. MCURF will posit that its research on the effect of digital therapeutics and psychedelic compounds on mental health will challenge our understanding of conventional mental health therapy. Nine more companies will post their arguments, but investors will only get to hear the full story at the forum.
The Life Science Investor Forum may present a window of opportunity for investors and traders, allowing them to hear exclusively from companies attempting to be health leaders of the future. The 1-day marathon event is free for everyone and requires only a simple email sign-up to join.
Life Sciences Investor Forum Agenda
A complete list of the agenda is available on the Life Science Investor Forum’s main page.
Time: 9:30 a.m. EST
Company: RedHill BioPharma Ltd.
Ticker: RDHL
Industry: Biopharmaceuticals — gastrointestinal and infectious diseases
Speaker information: Guy Goldberg, Chief Business Officer
Time: 10 a.m. EST
Company: RespireRx Pharmaceuticals Inc.
Ticker: RSPI
Industry: Biopharmaceuticals — psychiatric and neurological disorders
Speaker information: Jeff Margolis, SVP, Treasurer, CFO and Member of Board of Directors
Time: 10:30 a.m. EST
Company: Relief Therapeutics Holding SA
Ticker: RLFTF
Industry: Biopharmaceuticals — respiratory and rare and specialty
Speaker information: Jack Weinstein, chief financial officer and treasurer
Time: 11 a.m. EST
Company: VolitionRx Limited
Ticker: VNRX
Industry: Epigenetics — cancer screening and veterinary
Speaker information: Scott Powell, head of investor relations and U.S. chief financial officer
Time: 11:30 a.m. EST
Company: Mind Cure Health Inc.
Ticker: MCURF
Industry: Pharmaceuticals — psychedelics and mental health
Speaker Information: Kelsey Ramsden, president and CEO
Time: 12 p.m. EST
Company: Alpha Cognition, Inc.
Tickers: ACOGF, ACOG
Industry: Biopharmaceuticals — Alzheimer’s disease and amyotrophic lateral sclerosis (ALS)
Speaker information: Michael McFadden, CEO
Time: 12:30 p.m. EST
Company: Emmaus Life Sciences Inc.
Ticker: EMMA
Industry: Biopharmaceuticals — rare and orphan diseases
Speaker information: Yutaka Niihara, CEO and chairman
Time: 1 p.m. EST
Company: Hemostemix Inc.
Tickers: HMTXF, HEM
Industry: Biotechnology — stem cell therapies
Speaker information: Thomas Smeenk, co-founder, president and CEO
Time: 1:30 p.m. EST
Company: Jack Nathan Medical Corp.
Tickers: JNHMF, (TSX:-V JNH)
Industry: Primary-care medical clinics
Speaker information: Glenn Copeland, CEO and chief medical officer, David Berman, chief financial officer
Time: 2 p.m. EST
Company: ReShape Lifesciences Inc.
Ticker: RSLS
Industry: Weight loss and metabolic health
Speaker information: Bart Bandy, CEO and president, Tom Stankovich, CFO
Time: 2:30 p.m. EST
Company: Else Nutrition Holdings Inc.
Ticker: BABYF, BABY
Industry: Plant-based nutrition
Speaker information: Hamutal Yitzhak, founder and CEO
Time: 3 p.m. EST
Company: Salarius Pharmaceuticals, Inc.
Ticker: SLRX
Industry: Biotechnology - Cancer
Speaker information: David Arthur, CEO
A complete list of the agenda is available on the Life Science Investor Forum’s main page.
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.